Teva reorganizes

Share this article:

Teva is undergoing an overhaul as of July 1. Among the changes announced Monday were the creation of a Global Generics Medicines group, which will handle launch and commercialization of its generics portfolio, as well as its over-the-counter business. Former Actavis president Sigurder Olafsson will head this new division.

Additional changes include a new Corporate Development Strategy and Innovation Group, and a new Global Corporate Marketing Excellence and Communications Group.

Teva, which recently found out it will soon navigate a world with generic Copaxone medications, has been facing a series of challenges, including a tumultuous leadership period which capped 2013. The company said in a statement that these changes “are another key step in Teva's strategic direction to create a less complex, integrated company.”

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

India's Marck gets FDA Warning Letter

Inspectors of Marck Biosciences found an array of problems during a October-November 2013 inspection, including mold near a sterile area that was so bad "the room had 'partially caved in.'"

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.